Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSRD-100 (Naftifine) in Atopic Dermatitis
NCT02677636Phase 3Withdrawn
- Sponsor
- Merz
- Primary completion
- Jul 2016
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of naftifine organogel (MediQuest Therapeutics) in atopic dermatitis (AD) (2 arms), sponsored by Merz. Primary endpoint: Proportion of subjects with treatment success at Day 28. Status: withdrawn.
02
Drugs
naftifine organogel (MediQuest Therapeutics)
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02677636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677636.